Histamine Synergistically Promotes Bfgf-Induced Angiogenesis by Enhancing Vegf Production Via H1 Receptor
Qian Lu,Chong Wang,Rong Pan,Xinghua Gao,Zhifeng Wei,Yufeng Xia,Yue Dai
DOI: https://doi.org/10.1002/jcb.24440
2013-01-01
Journal of Cellular Biochemistry
Abstract:Histamine, a major mediator present in mast cells that is released into the extracellular milieu upon degranulation, is well known to possess a wide range of biological activities in several classic physiological and pathological processes. However, whether and how it participates in angiogenesis remains obscure. In the present study, we observed its direct and synergistic action with basic fibroblast growth factor (bFGF), an important inducer of angiogenesis, on in vitro angiogenesis models of endothelial cells. Data showed that histamine (0.1, 1, 10 mu M) itself was absent of direct effects on the processes of angiogenesis, including the proliferation, migration, and tube formation of endothelial cells. Nevertheless, it could concentration-dependently enhance bFGF-induced angiogenesis as well as production of vascular endothelial growth factor (VEGF) from endothelial cells. The synergistic effect of histamine on VEGF production could be reversed by pretreatments with diphenhydramine (H1-receptor antagonist), SB203580 (selective p38 mitogen-activated protein kinase (MAPK) inhibitor) and L-NAME (nitric oxide synthase (NOS) inhibitor), but not with cimetidine (H2-receptor antagonist) and indomethacin (cyclooxygenase (COX) inhibitor). Moreover, histamine could augment bFGF-incuced phosphorylation and degradation of IB, a key factor accounting for the activation and translocation of nuclear factor B (NF-B) in endothelial cells. These findings indicated that histamine was able to synergistically augment bFGF-induced angiogenesis, and this action was linked to VEGF production through H1-receptor and the activation of endothelial nitric oxide synthase (eNOS), p38 MAPK, and IB in endothelial cells. J. Cell. Biochem. 114: 10091019, 2013. (c) 2012 Wiley Periodicals, Inc.